Listar MD - Artículos por autor "Ribelles, Nuria"
Mostrando ítems 1-10 de 10
-
A Carboxylesterase 2 Gene Polymorphism as Predictor of Capecitabine on Response and Time to Progression
Ribelles, Nuria; López-Siles, J; Sánchez-Muñoz, Alfonso
; Sánchez, E; González, E; Sánchez, MJ; Carabantes, F; Sánchez- Rovira, P; Márquez, A; Dueñas, R; Sevilla, I; Alba-Conejo, Emilio[et al.] (Bentham Science Publishers Ltd, 2008)
Capecitabine is a drug that requires the consecutive action of three enzymes: carboxylesterase 2 (CES 2), cytidine deaminase (CDD), and thymidine phosphorylase (TP) for transformation into 5-fluorouracil (5FU). The ... -
A microRNA signature associated with early recurrence in breast cancer.
Pérez-Rivas, Luis G.; Jerez-Aragonés, José Manuel; Carmona, Rosario; De Luque, Vanessa; Vicioso-Recio, Luis Prudencio; Claros-Díaz, Manuel Gonzalo; Viguera-Mínguez, Enrique; Pajares, Bella; Sánchez-Muñoz, Alfonso; Ribelles, Nuria; Alba-Conejo, Emilio; Lozano-Castro, José[et al.] (PLOS, 2014-03-14)
Recurrent breast cancer occurring after the initial treatment is associated with poor outcome. A bimodal relapse pattern after surgery for primary tumor has been described with peaks of early and late recurrence occurring ... -
A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study
Alba-Conejo, Emilio; Chacón, J. L.; Lluc, A.; Antón, A.; Estévez, L.; Cirauqui, B.; Carrasco, E.; Calvo, L.; Seguí, M.A.; Ribelles, Nuria; Álvarez, R.; Sánchez-Muñoz, Alfonso; Sánchez, R.; Lopez Garcia-Asenjo, J.A.; Rodriguez-Martin, C.; Escudero, M.J.; Albanell, J.[et al.] (Springer, 2012-10)
Abstract Chemotherapy remains as the only systemic treatment option available for basal-like breast cancer (BC) patients. Preclinical models and several phase II studies suggested that platinum salts are active drugs in ... -
Deciphering HER2 Breast Cancer Disease: Biological and Clinical Implications.
Godoy-Ortiz, Ana; Sánchez-Muñoz, Alfonso; Chica Parrado, María del Rosario; Álvarez-Pérez, Martína; Ribelles, Nuria; Rueda-Domínguez, Antonio; Alba-Conejo, Emilio[et al.] (Frontiers Media, 2019)
The main obstacle for designing effective treatment approaches in breast cancer is the extensive and the characteristic heterogeneity of this tumor. The vast majority of critical genomic changes occurs during breast cancer ... -
Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World Data.
Díaz-Redondo, Tamara; Lavado Valenzuela, Rocío; Jiménez-Rodríguez, Begoña; Pascual, Tomás; Gálvez, Fernando; Falcón, Alejandro; Álamo, María del Carmen; Morales-Estévez, Cristina; Amerigo, Marta; Pascual, Javier; Sánchez-Muñoz, Alfonso; González-Guerrero, Macarena; Vicioso-Recio, Luis Prudencio; Laborda-Illanes, Aurora; Ortega-Jiménez, María Victoria; Pérez-Villa, Lidia; Fernández-Martínez, Aranzazu; Chic, Nuria; Jerez-Aragonés, José Manuel; Álvarez-Pérez, Martína; Prat, Aleix; Ribelles, Nuria; Alba-Conejo, Emilio[et al.] (Frontiers Media, 2019)
Double blockade with pertuzumab and trastuzumab combined with chemotherapy is the standard neoadjuvant treatment for HER2-positive early breast cancer. Data derived from clinical trials indicates that the response rates ... -
Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer.
Sánchez-Muñoz, Alfonso; Gallego-Domínguez, Elena María; De Luque, Vanessa; Pérez-Rivas, Luis G.; Vicioso-Recio, Luis Prudencio; Ribelles, Nuria; Lozano-Castro, José; Alba-Conejo, Emilio[et al.] (Springer Nature, 2010-04-13)
Background: Mutational analysis of the KRAS gene has recently been established as a complementary in vitro diagnostic tool for the identification of patients with colorectal cancer who will not benefit from anti-epidermal ... -
Machine learning and natural language processing (NLP) approach to predict early progression to first-line treatment in real-world hormone receptor-positive (HRþ)/HER2-negative advanced breast cancer patients.
Ribelles, Nuria; Jerez-Aragonés, José Manuel; Rodríguez-Brazzarola, Pablo; Jiménez-Rodríguez, Begoña; Díaz-Redondo, Tamara; Mesa, Héctor; Márquez, Antonia; Sánchez-Muñoz, Alfonso; Pajares, Bella; Carabantes, Francisco; Bermejo-Pérez, María José; Villar, Ester; Domínguez-Recio, María Emilia; Saez-Lara, Enrique; Gálvez Carvajal, Laura; Godoy-Ortiz, Ana; Franco, Leónardo; Ruiz-Medina, Sofía; López, Irene; Alba-Conejo, Emilio[et al.] (Elsevier, 2021)
Background: CDK4/6 inhibitors plus endocrine therapies are the current standard of care in the first-line treatment of HRþ/HER2-negative metastatic breast cancer, but there are no well-established clinical or molecular ... -
Pattern of recurrence of early breast cancer is different according to intrinsic subtype and proliferation index.
Ribelles, Nuria; Jerez-Aragonés, José Manuel; Pajares, Bella; Vicioso-Recio, Luis Prudencio; Jiménez-Rodríguez, Begoña; De Luque, Vanessa; Franco, Leónardo; Gallego-Domínguez, Elena María; Márquez, Antonia; Álvarez, Martina; Sánchez-Muñoz, Alfonso; Pérez-Rivas, Luis G.; Alba-Conejo, Emilio; Ribelles, Nuria[et al.] (BMC, 2013-10-22)
Recurrence risk in breast cancer varies throughout the follow-up time. We examined if these changes are related to the level of expression of the proliferation pathway and intrinsic subtypes. Results: Luminal A displayed ... -
Serum protein levels following surgery in breast cancer patients: A protein microarray approach
Pérez-Rivas, Luis G.; Jérez, J.M.; Fernández-De Sousa, C.E.; De Luque, Vanessa; Quero, C.; Pajares, Bella; Franco, L.; Sánchez-Muñoz, Alfonso; Ribelles, Nuria; Alba-Conejo, Emilio[et al.] (Spandidos Publications, 2012-07)
Surgery is the primary treatment for non-metastatic breast cancer. However, the risk of early recurrence remains after surgical removal of the primary tumor. Recurrence is suggested to result from hidden micrometastatic ... -
Targeted treatment approaches in refractory germ cell tumors
Gálvez Carvajal, Laura; Sánchez-Muñoz, Alfonso; Ribelles, Nuria; Saez, Maribel; Baena, Javier; Ruiz, Sofía; Ithurbisquy, Catherine; Alba-Conejo, Emilio[et al.] (Elsevier, 2019)
Germ cell tumors (GCTs) are the most common type of solid tumor amongst patients between 15 and 35 years of age. They are also one of the types of tumor with the highest cure rate, due to their high sensitivity to cisplatin ...